|
1
|
Yuan X, Zhang W, He Y, Yuan J, Song D,
Chen H, Qin W, Qian X, Yu H and Guo Z: Proteomic analysis of
cisplatin- and oxaliplatin-induced phosphorylation in proteins
bound to Pt-DNA adducts. Metallomics. 12:1834–1840. 2020.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Spanish Agency for Medicines and Health
Products (AEMPS): Technical datasheet of oxaliplatin. AEMPS,
Madrid, 2021. https://cima.aemps.es/cima/publico.html. Accessed
January 22, 2021.
|
|
3
|
Goodsell DS: The molecular perspective:
Cisplatin. Oncologist. 11:316–317. 2006.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Bahadori F and Demiray M: Management of
extravasation of oxaliplatin by mimicking its biotransformation.
Clin Transl Oncol. 20:1353–1357. 2018.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Baur M, Kienzer HR, Rath T and Dittrich C:
Extravasation of oxaliplatin (Eloxatin((R)))-clinical course.
Onkologi. 23:468–471. 2000.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Pérez Fidalgo JA, García Fabregat L,
Cervantes A, Margulies A, Vidall C and Roila F: ESMO Guidelines
Working Group. Management of chemotherapy extravasation: ESMO-EONS
clinical practice guidelines. Ann Oncol. 23 (Suppl
7):vii167–vii173. 2012.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Pericay C, López A, Soler JR, Bonfill T,
Dotor E and Saigí E: Extravasation of oxaliplatin: An infrequent
and irritant toxicity. Clin Transl Oncol. 11:114–116.
2009.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Wickham R, Engelking C, Sauerland C and
Corbi D: Vesicant extravasation part II: Evidence-based management
and continuing controversies. Oncol Nurs Forum. 33:1143–1150.
2006.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Kreidieh FY, Moukadem HA and El Saghir NS:
Overview, prevention and management of chemotherapy extravasation.
World J Clin Oncol. 7:87–97. 2016.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Narducci F, Jean-Laurent M, Boulanger L,
El Bédoui S, Mallet Y, Houpeau JL, Hamdani A, Penel N and Fournier
C: Totally implantable venous access port systems and risk factors
for complications: A one-year prospective study in a cancer centre.
Eur J Surg Oncol. 37:913–918. 2011.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Masters B, Hickish T and Cidon EU: A
midline for oxaliplatin infusion: The myth of safety devices. BMJ
Case Rep. 2014(bcr2014204360)2014.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Boesen C and Nielsen SE: Reversible tissue
damage after paravasal infusion of oxaliplatin. Ugeskr Laeger.
177(V07140390)2015.PubMed/NCBI(In Danish).
|
|
13
|
Leon-Ferre RA, Abu Hejleh TB and
Halfdanarson TR: Extravasation of oxaliplatin into the mediastinum:
A case report and review of the literature. Clin Adv Hematol Oncol.
10:546–548. 2012.PubMed/NCBI
|
|
14
|
Haslik W, Hacker S, Felberbauer FX,
Thallinger C, Bartsch R, Kornauth C, Deutschmann C and Mader RM:
Port-a-Cath extravasation of vesicant cytotoxics: Surgical options
for a rare complication of cancer chemotherapy. Eur J Surg Oncol.
41:378–385. 2015.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Azaïs H, Bresson L, Bassil A, Katdare N,
Merlot B, Houpeau JL, El Bedoui S, Meurant JP, Tresch E and
Narducci F: Chemotherapy drug extravasation in totally implantable
venous access port systems: How effective is early surgical lavage?
J Vasc Access. 16:31–37. 2015.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Makrilia N, Syrigou E, Kaklamanos I,
Manolopoulos L and Saif MW: Hypersensitivity reactions associated
with platinum antineoplastic agents: A systematic review. Met Based
Drugs. 2010(207084)2010.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Sorich J, Taubes B, Wagner A and Hochster
H: Oxaliplatin: Practical guidelines for administration. Clin J
Oncol Nurs. 8:251–256. 2004.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Markman M: Toxicities of the platinum
antineoplastic agents. Expert Opin Drug Saf. 2:597–607.
2003.PubMed/NCBI View Article : Google Scholar
|
|
19
|
de Lemos ML and Walisser S: Management of
extravasation of oxaliplatin. J Oncol Pharm Pract. 11:159–162.
2005.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Kretzschmar A, Pink D, Thuss-Patience P,
Dörken B, Reichert P and Eckert R: Extravasations of oxaliplatin. J
Clin Oncol. 21:4068–4069. 2003.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Foo KF, Michael M, Toner G and Zalcberg J:
A case report of oxaliplatin extravasation. Ann Oncol. 14:961–962.
2003.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Conde-Estévez D and Mateu-de Antonio J:
Update in the management of extravasations of cytocytostatic agent.
Farm Hosp. 36:34–42. 2012.PubMed/NCBI View Article : Google Scholar : (In Spanish).
|
